Lycopene Dietary Intervention: A pilot study in patients with heart failure

Journal of Cardiovascular Nursing

Volumn 30, Issue 3, 2015, Pages 205-212

  Biddle, Martha J ^a   Lennie, Terry A ^a   Bricker, Gregory V ^b   Kopec, Rachel E ^b   Schwartz, Steven J ^b   Moser, Debra K ^a  

^a UNIVERSITY OF KENTUCKY COLLEGE OF NURSING   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

biomakers; cardiovascular disease; heart failure; inflammation; lycopene diet

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CAROTENOID; LYCOPENE; URIC ACID;

AGED; BEVERAGE; BLOOD; CONTROLLED STUDY; DIET THERAPY; FEMALE; HEART FAILURE; HUMAN; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

AGED; ANTIOXIDANTS; BEVERAGES; BIOMARKERS; C-REACTIVE PROTEIN; CAROTENOIDS; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PILOT PROJECTS; SEX FACTORS; URIC ACID;

EID: 84928586617     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/JCN.0000000000000108     Document Type: Article

References (59)

1. Blecker S, Paul M, Taksler G, Ogedegbe G, Katz S. Heart failureYassociated hospitalizations in the united states. J Am Coll Cardiol. 2013;61:1259-1267.
2. Gheorghiade M, Shah AN, Vaduganathan M, et al. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: Academics', clinicians', industry's, regulators', and payers' perspectives. Heart Fail Clin. 2013;9:285-290.
3. Miller LW, Missov ED. Epidemiology of heart failure. Cardiol Clin. 2001;19:547-555.
4. Starling RC. The heart failure pandemic: changing patterns, costs, and treatment strategies. Cleve Clin J Med. 1998;65: 351-358.
5. Seferovic PM, Stoerk S, Filippatos G, et al. Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. Eur J Heart Fail. 2013;15:947-959.
6. Kannel WB. Vital epidemiologic clues in heart failure. J Clin Epidemiol. 2000;53:229-235.
7. Hak AE, Stampfer MJ, Campos H, et al. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low-risk population of us male physicians. Circulation. 2003;108:802-807.
8. Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am J Clin Nutr. 2004;79:47-53.
9. Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. J Am Coll Nutr. 2000;19:563-569.
10. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, Boeing H, Hofman A, Witteman JC. Serum carotenoids and atherosclerosis: TheRotterdamStudy. Atherosclerosis. 2000;148:49-56.
11. Heymans S, Hirsch E, Anker SD, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society Of Cardiology. Eur J Heart Fail. 2009;11:119-129.
12. Mann DL. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95:9CY16C. Discussion 38CY40C.
13. Deswal A, Petersen NJ, Feldman AM, Young JB,White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the vesnarinone trial (vest). Circulation. 2001;103:2055-2059.
14. Rissanen TH, Voutilainen S, NyyssonenK, Salonen R, Kaplan GA, Salonen JT. Serum lycopene concentrations and carotid atherosclerosis: The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr. 2003;77:133-138.
15. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest. 2001;120: 2035-2046.
16. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des. 2004;10:1699-1711.
17. Thomson MJ, Puntmann V, Kaski JC. Atherosclerosis and oxidant stress: The end of the road for antioxidant vitamin treatment? Cardiovasc Drugs Ther. 2007;21:195-210.
18. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med. 2000; 28:1780-1794.
19. Trachtenberg BH, Hare JM. Biomarkers of oxidative stress in heart failure. Heart Fail Clin. 2009;5:561-577.
20. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44-84.
21. Levitan EB,WolkA,MittlemanMA. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. Am J Cardiol. 2009;104:1416-1420.
22. Pfister R, Sharp SJ, Luben R, Wareham NJ, Khaw KT. Plasma vitamin c predicts incident heart failure in men and women in European Prospective Investigation Into Cancer andNutritionYNorfolk Prospective Study.Am Heart J. 2011; 162:246-253.
23. Arab L, Steck S. Lycopene and cardiovascular disease. Am J Clin Nutr. 2000;71:1691SY1695S. Discussion 1696SY1697S.
24. Kohlmeier L, Hastings SB. Epidemiologic evidence of a role of carotenoids in cardiovascular disease prevention. Am J Clin Nutr. 1995;62:1370SY1376S.
25. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians' Health Study II Randomized Controlled Trial. JAMA. 2008;300:2123-2133.
26. AlbertCM, CookNR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA. 2008;299:2027-2036.
27. Doust J, Lehman R, Glasziou P. The role of BNP testing in heart failure. Am Fam Physician. 2006;74:1893-1898.
28. Maisel A. Updated algorithms for using b-type natriuretic peptide (BNP) levels in the diagnosis and management of congestive heart failure. Crit Pathw Cardiol. 2004;3:144-149.
29. Shemesh T, Rowley KG, Shephard M, Piers LS, O'Dea K. Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point-of-care methods in remote Australian aboriginal communities. Clin Chim Acta. 2006;367:69-76.
30. Azzazy HM, Christenson RH, Duh SH. Stability of b-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the biosite triage or Beckman-Coulter access systems. Clin Chim Acta. 2007;384:176-178.
31. Harnack L, Stevens M, Van Heel N, Schakel S, Dwyer JT, Himes J. A computer-based approach for assessing dietary supplement use in conjunction with dietary recalls. J Food Compost Anal. 2008;21:S78YS82.
32. Campbells. V8 juice 100% vegetable juice. 2010. http://v8juice .com/Products.aspx?SectionID=v8. Accessed June 1, 2010.
33. Polidori MC, Savino K, Alunni G, et al. Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radic BiolMed. 2002;32:148-152.
34. Polidori MC, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail. 2004;10:334-338.
35. Chung ML, Moser DK, Lennie TA, et al. Gender differences in adherence to the sodium-restricted diet in patients with heart failure. J Card Fail. 2006;12:628-634.
36. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-1848.
37. Rexrode KM, Pradhan A,Manson JE, Buring JE, Ridker PM. Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol. 2003;13:674-682.
38. Testa G, Cacciatore F, Galizia G, et al. Waist circumference but not bodymass index predicts long-termmortality in elderly subjects with chronic heart failure. J Am Geriatr Soc. 2010; 58:1433-1440.
39. Hu G, Jousilahti P, Antikainen R, Katzmarzyk PT, Tuomilehto J. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121:237-244.
40. Patel VB, Robbins MA, Topol EJ. C-reactive protein: A 'goldenmarker' for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68:521-524, 527-534.
41. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-843.
42. Gallagher R,McKinley S, Dracup K. Predictors of women's attendance at cardiac rehabilitation programs. Prog Cardiovasc Nurs. 2003;18:121-126.
43. Lavie CJ, Milani R. Secondary coronary prevention in women: it starts with cardiac rehabilitation, exercise, and fitness. J Womens Health (Larchmt). 2009;8:1115-1117.
44. MacInnes JD. The illness perceptions of women following acute myocardial infarction: implications for behaviour change and attendance at cardiac rehabilitation. Women Health. 2005;42:105-121.
45. WorcesterMU, MurphyBM,Mee VK, Roberts SB, Goble AJ. Cardiac rehabilitation programmes: predictors of nonattendance and drop-out. Eur J Cardiovasc Prev Rehabil. 2004;11:328-335.
46. Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Heymsfield SB, Nguyen AM. Predictors of attrition and weight loss success: results from a randomized controlled trial. Behav Res Ther. 2009;47:685-691.
47. Presnell K, Pells J, Stout A, Musante G. Sex differences in the relation of weight loss self-efficacy, binge eating, and depressive symptoms to weight loss success in a residential obesity treatment program. Eat Behav. 2008;9:170-180.
48. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165-2168.
49. Gabriel AS, Martinsson A,Wretlind B, Ahnve S. IL-6 levels in acute and post myocardial infarction: Their relation to CRP levels, infarction size, left ventricular systolic function, and heart failure. Eur J Intern Med. 2004;15:523-528.
50. Michowitz Y, Arbel Y, Wexler D, et al. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol. 2008;125:347-351.
51. Romeo R, Scalisi C, Tafuri L, Romeo A, Maugeri D, Sorace R. Different characteristics of chronic heart failure (CHF) in elderly diabetics and non-diabetics. Arch Gerontol Geriatr. 2009;1:101-104.
52. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-1434.
53. Poland B, Frohlich K, Haines RJ,Mykhalovskiy E, RockM, Sparks R. The social context of smoking: The next frontier in tobacco control? Tob Control. 2006;15:59-63.
54. Hadley CW, Clinton SK, Schwartz SJ. The consumption of processed tomato products enhances plasma lycopene concentrations in association with a reduced lipoprotein sensitivity to oxidative damage. J Nutr. 2003;133:727-732.
55. Agarwal A, Shen H, Agarwal S, Rao AV. Lycopene content of tomato products: its stability, bioavailability and in vivo antioxidant properties. J Med Food. 2001;4:9-15.
56. He J,Ogden LG, Bazzano LA,Vupputuri S, Loria C, Whelton PK. Dietary sodium intake and incidence of congestive heart failure in overweight us men and women: First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Arch Intern Med. 2002;162:1619-1624.
57. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA. 1999; 282:2027-2034.
58. Bentley B,De Jong MJ,MoserDK, Peden AR. Factors related to nonadherence to low sodium diet recommendations in heart failure patients. Eur J Cardiovasc Nurs. 2005;4:331-336.
59. Biddle M. Lycopene intake predicts event-free survival in patients with heart failure. Circulation. 2008;118:S920.